Last reviewed · How we verify

Miacalcin Calcitonin Salmon Nasal Spray

University of Missouri-Columbia · FDA-approved active Small molecule

Miacalcin Calcitonin Salmon Nasal Spray is a Calcitonin receptor agonist Small molecule drug developed by University of Missouri-Columbia. It is currently FDA-approved for Osteoporosis in postmenopausal women, Paget's disease of bone, Hypercalcemia of malignancy. Also known as: Miacalcin, Calcitonin.

Calcitonin salmon is a peptide hormone that binds to calcitonin receptors on osteoclasts to inhibit bone resorption and increase urinary calcium excretion.

Calcitonin salmon is a peptide hormone that binds to calcitonin receptors on osteoclasts to inhibit bone resorption and increase urinary calcium excretion. Used for Osteoporosis in postmenopausal women, Paget's disease of bone, Hypercalcemia of malignancy.

At a glance

Generic nameMiacalcin Calcitonin Salmon Nasal Spray
Also known asMiacalcin, Calcitonin
SponsorUniversity of Missouri-Columbia
Drug classCalcitonin receptor agonist
TargetCalcitonin receptor
ModalitySmall molecule
Therapeutic areaEndocrinology / Bone Metabolism
PhaseFDA-approved

Mechanism of action

Calcitonin salmon mimics the natural human calcitonin hormone and acts as an osteoclast inhibitor, reducing bone turnover and resorption. It also promotes renal calcium excretion and has analgesic properties in bone pain conditions. The nasal spray formulation allows systemic absorption for treatment of osteoporosis and hypercalcemia.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Miacalcin Calcitonin Salmon Nasal Spray

What is Miacalcin Calcitonin Salmon Nasal Spray?

Miacalcin Calcitonin Salmon Nasal Spray is a Calcitonin receptor agonist drug developed by University of Missouri-Columbia, indicated for Osteoporosis in postmenopausal women, Paget's disease of bone, Hypercalcemia of malignancy.

How does Miacalcin Calcitonin Salmon Nasal Spray work?

Calcitonin salmon is a peptide hormone that binds to calcitonin receptors on osteoclasts to inhibit bone resorption and increase urinary calcium excretion.

What is Miacalcin Calcitonin Salmon Nasal Spray used for?

Miacalcin Calcitonin Salmon Nasal Spray is indicated for Osteoporosis in postmenopausal women, Paget's disease of bone, Hypercalcemia of malignancy.

Who makes Miacalcin Calcitonin Salmon Nasal Spray?

Miacalcin Calcitonin Salmon Nasal Spray is developed and marketed by University of Missouri-Columbia (see full University of Missouri-Columbia pipeline at /company/university-of-missouri-columbia).

Is Miacalcin Calcitonin Salmon Nasal Spray also known as anything else?

Miacalcin Calcitonin Salmon Nasal Spray is also known as Miacalcin, Calcitonin.

What drug class is Miacalcin Calcitonin Salmon Nasal Spray in?

Miacalcin Calcitonin Salmon Nasal Spray belongs to the Calcitonin receptor agonist class. See all Calcitonin receptor agonist drugs at /class/calcitonin-receptor-agonist.

What development phase is Miacalcin Calcitonin Salmon Nasal Spray in?

Miacalcin Calcitonin Salmon Nasal Spray is FDA-approved (marketed).

What are the side effects of Miacalcin Calcitonin Salmon Nasal Spray?

Common side effects of Miacalcin Calcitonin Salmon Nasal Spray include Nasal irritation or rhinitis, Nausea, Flushing, Headache, Nasal congestion.

What does Miacalcin Calcitonin Salmon Nasal Spray target?

Miacalcin Calcitonin Salmon Nasal Spray targets Calcitonin receptor and is a Calcitonin receptor agonist.

Related